Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pump could ease cancer pain without heavy drugs

NCT ID NCT07427888

Symptom relief Sponsor: Institute of Oncology Ljubljana Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an implantable pump that delivers pain medicine directly into the spinal fluid for people with hard-to-treat cancer pain. Eight patients with advanced cancer and severe pain despite strong opioids took part. The goal was to see if the pump could provide better pain relief with fewer side effects than a standard pump placed under the skin.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
implantable intrathecal pump (device delivering analgesic medication directly into spinal fluid)
What this could lead to
If it works, this could offer a more effective and less side-effect-heavy way to manage severe cancer pain for patients who don't respond to standard treatments.
What could go wrong
This was a very small study (8 people) with no phase designation, so results may not apply broadly. The pump requires surgery and carries risks like infection or device malfunction.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

8 people

The number who actually took part.

Started

Oct 2022

Finished

Oct 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with advanced malignant disease. * Age between 40 and 80 years. * Cancer-related pain with intensity ≥ 5 on the Visual Analogue Scale (VAS) or Numerical Rating Scale (NRS) despite optimized conventional analgesic therapy. * Daily opioid requirement equivalent to ≥ 200 mg oral morphine, or inability to tolerate systemic opioid therapy due to adverse effects. * Expected life expectancy of at least 6 months. * Physical condition allowing implantation of an intrathecal pump or use of a subcutaneous infusion pump. * Ability to understand the study procedures and provide written informed consent Exclusion Criteria: * Refusal or inability to provide informed consent. * Severe cardiac disease (NYHA class \> III). * Severe chronic obstructive pulmonary disease (FEV1 \< 40%). * Presence of significant neurological disease. * Presence of severe psychiatric disorder. * Regular use of psychotropic medications that could interfere with pain assessment. * Age younger than 40 years or older than 80 years.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced malignant disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer Cancer Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer pain Neoplasm-related pain

Contacts and locations

Locations

  • Institute of Oncology Ljubljana

    Ljubljana, 1000, Slovenia

More trials for these conditions

Other studies related to the condition(s) this trial covers.